STOCK TITAN

Axonics® to Participate in BofA Securities 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Axonics, a medical technology company, will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 12:20 p.m. ET. The presentation will be available via live webcast and on their investor relations website. Based in Irvine, California, Axonics specializes in innovative solutions for bladder and bowel dysfunction, including sacral neuromodulation systems and Bulkamid® for urinary incontinence. The company ranks No. 1 on Deloitte's 2021 Technology Fast 500 and among the top 500 fastest-growing companies by the Financial Times.

Positive
  • None.
Negative
  • None.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022.

Axonics is scheduled to present at 12:20 p.m. Eastern Time. A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations website.

About Axonics
Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Axonics’ sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Axonics contact:

Neil Bhalodkar

949-336-5293

ir@axonics.com

Source: Axonics, Inc.

FAQ

When is Axonics participating in the BofA Securities 2022 Healthcare Conference?

Axonics will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022.

What time will Axonics present at the conference?

Axonics is scheduled to present at 12:20 p.m. Eastern Time.

Where can I watch Axonics' conference presentation?

The presentation will be accessible via live webcast on Axonics' investor relations website.

What products does Axonics offer for bladder and bowel dysfunction?

Axonics offers sacral neuromodulation systems and Bulkamid® for treating bladder and bowel dysfunction.

What recognition has Axonics received for its growth?

Axonics was ranked No. 1 on Deloitte's 2021 Technology Fast 500 and among the Financial Times' 500 fastest-growing companies.

Axonics, Inc.

NASDAQ:AXNX

AXNX Rankings

AXNX Latest News

AXNX Stock Data

3.63B
50.43M
1.26%
87.22%
6.48%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
IRVINE